Stockscreener 앱 받기
5.03
5.01%
0.24
전일 마감가:
$4.79
열려 있는:
$4.76
하루 거래량:
102.37K
Relative Volume:
0.74
시가총액:
$130.46M
수익:
$40,000
순이익/손실:
$-38.64M
주가수익비율:
-2.7316
EPS:
-1.8414
순현금흐름:
$-22.21M
1주 성능:
+7.25%
1개월 성능:
+46.65%
6개월 성능:
-47.77%
1년 성능:
-32.66%
1일 변동 폭
$4.74
$5.195
1주일 범위
$4.60
$5.195
52주 변동 폭
$3.005
$12.99
Neonc Technologies Holdings Inc Stock (NTHI) Company Profile
명칭
Neonc Technologies Holdings Inc
전화
310 663 7831
주소
23975 PARK SORRENTO, CALABASAS
Compare NTHI vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTHI
Neonc Technologies Holdings Inc
|
5.03 | 118.27M | 40,000 | -38.64M | -22.21M | -1.8414 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neonc Technologies Holdings Inc Stock (NTHI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-19 | 개시 | Alliance Global Partners | Buy |
| 2026-05-18 | 개시 | Maxim Group | Buy |
| 2026-04-24 | 개시 | BTIG Research | Buy |
Neonc Technologies Holdings Inc 주식(NTHI)의 최신 뉴스
NeOnc Technologies (NASDAQ: NTHI) names Shomali to audit panel - Stock Titan
Neonc Technologies CEO Thomas C. Chen acquires $70,010 of common shares via IRA - Bitget
NeOnc Technologies Holds 2026 Annual Stockholder Meeting - The Globe and Mail
Neonc Technologies CEO Thomas Chen buys $69,997 in stock - Investing.com
Neonc Technologies CSO Thomas Chen buys $192,899 in stock - Investing.com
NeOnc Technologies (NTHI) CEO adds 12.8K-share IRA stake - Stock Titan
NeOnc Technologies (NTHI) investors approve equity plan, elect two directors - Stock Titan
Founder of NeOnc Technologies Holdings Thomas Chen Buys 1.0% More Shares - simplywall.st
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t - Sahm
NeOnc Technologies (NTHI) CEO boosts stake with August open‑market buys - Stock Titan
Neonc Technologies CEO Amir Heshmatpour acquires $49,860 in stock - Investing.com
Neonc Technologies CEO Amir Heshmatpour acquires $49,860 in stock By Investing.com - Investing.com Canada
NeOnc (NTHI) CEO lifts direct stake to 3,096,000 shares - Stock Titan
NeOnc Technologies Holdings CEO Continues Open-Market Buying Following NEO100 Phase 2a Results and Elevated Short Interest - Quiver Quantitative
Neonc Technologies CEO buys $58,579 in company shares By Investing.com - Investing.com Australia
NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results - Sahm
Neonc Technologies CEO buys $58,579 in company shares - Investing.com
NeOnc Technologies (NTHI) CEO adds stock in two August buys - Stock Titan
NeOnc Technologies Holdings, Inc. Common Stock (NASDAQ: NTHI) Stock Price, News & Analysis - Kalkine
Duos Technologies Group Sets Second Quarter 2026 Earnings Call for Monday, August 17, 2026 at 4:30 PM ET - Stocktwits
NeOnc Technologies Holdings' Phase 2a Results Strengthen the Case for Its Nasdaq-Backed Capital Strategy - Moomoo
NeOnc Technologies Holdings’ Phase 2a Results Strengthen the Case for Its Nasdaq-Backed Capital Strategy - Quiver Quantitative
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results - Moomoo
NeOnc Technologies Holdings Inc (NTHI) (Q2 2026) Earnings Call Highlights: First Annual Meeting ... By GuruFocus - Investing.com Canada
NTHI: All proposals, including director elections and plan amendments, were approved without questions - TradingView
Maxim Group Maintains NeOnc Technologies(NTHI.US) With Buy Rating, Maintains Target Price $20 - Moomoo
NeOnc Reports 26.1-Month Median Overall Survival in Phase 2a Brain Cancer Trial - Minichart
NeOnc Technologies holds investor call to discuss Phase 2a NEO100-01 results By Investing.com - Investing.com Nigeria
Form 8K Neonc Technologies Holdings Inc For: 13 August By Investing.com - Investing.com Canada
NeOnc Technologies (NTHI) NEO100 Phase 2a Readout Clears Primary Endpoint, FDA Meeting Planned - kalkine.ca
The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech - The Manila Times
NeOnc Technologies Holdings’ NEO100 Phase 2a Results Highlight Intranasal Brain-Delivery Platform Potential - Quiver Quantitative
NeOnc's Nasal Drug Delivery Strategy Reached a Brain-Cancer Trial - Stock Titan
Why is Neonc Technologies stock surging today? By Investing.com - Investing.com South Africa
Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer - The Manila Times
NeOnc Technologies Holdings Reports Positive Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma - Quiver Quantitative
NeOnc Technologies stock jumps on positive glioma trial data By Investing.com - Investing.com Australia
NeOnc Technologies shares jump after positive Phase 2a glioma results - Yahoo Finance
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x - Yahoo Finance
Why is Neonc Technologies stock surging today? - Investing.com
$NeOnc Technologies (NTHI.US)$ $NTHI plans an FDA Type B meeting to align the registrational path, signaling trial for accelerated approval. Clinical breakthrough could unlock financing and partnerships for NTHI's funding, milestone payments and markers - Moomoo
NeOnc Technologies Reports Positive Phase 2a Glioma Results - TipRanks
Form 8K Neonc Technologies Holdings Inc For: 12 August By Investing.com - Investing.com India
NeOnc reports phase 2a glioma trial meets primary endpoint By Investing.com - Investing.com Australia
NeOnc reports phase 2a glioma trial meets primary endpoint - Investing.com
$NTHI Mr. Heshmatpour CEO invested nearly $1 million of personal capital into NeOnc shares. In recent Months, he has purchased over $500,000 in the open market, as reflected in Form 4 filings with the U.S. Securities and Exchange Commission, with furthe - Moomoo
NeOnc Technologies stock jumps on positive glioma trial data - Investing.com
NeOnc Technologies Reports Positive Phase 2a NEO100 Results; Median OS 26.09 Months, PFS-6 48.9% - TradingView
Why is NeOnc Technologies stock surging today? By Investing.com - Investing.com Canada
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma - The Manila Times
Neonc Technologies Holdings Inc (NTHI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Neonc Technologies Holdings Inc 주식 (NTHI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| CHEN THOMAS C | CEO |
Aug 14 '26 |
Buy |
3.85 |
33,787 |
130,002 |
581,059 |
| CHEN THOMAS C | CEO |
Aug 17 '26 |
Buy |
4.04 |
2,472 |
9,998 |
583,531 |
| Heshmatpour Amir F | CEO, President |
Aug 18 '26 |
Buy |
5.54 |
9,000 |
49,860 |
3,096,000 |
| Heshmatpour Amir F | CEO, President |
Aug 14 '26 |
Buy |
3.79 |
12,000 |
45,460 |
3,084,000 |
| Heshmatpour Amir F | CEO, President |
Aug 17 '26 |
Buy |
4.37 |
3,000 |
13,120 |
3,087,000 |
| Heshmatpour Amir F | President |
May 01 '26 |
Buy |
4.16 |
10,000 |
41,592 |
3,072,000 |
| Heshmatpour Amir F | President |
Apr 28 '26 |
Buy |
4.52 |
10,000 |
45,180 |
3,062,000 |
| Neman-Ebrahim Yousha | Chief Clinical Officer |
Apr 23 '26 |
Buy |
4.88 |
500 |
2,440 |
134,760 |
| Heshmatpour Amir F | President |
Apr 23 '26 |
Buy |
4.90 |
10,000 |
49,000 |
3,052,000 |
| SUH, DAVID JR. | Chief Accounting Officer |
Apr 09 '26 |
Buy |
5.00 |
200 |
1,000 |
111,866 |
0.86%
0.31%
자본화:
|
볼륨(24시간):